Diabetes and Cancer

Epidemiologic evidence suggests that cancer incidence is associated with diabetes as well as certain diabetes risk factors and diabetes treatments. This consensus statement of experts assembled jointly by the American Diabetes Association and the American Cancer Society reviews the state of science concerning 1) the association between diabetes and cancer incidence or prognosis, 2) risk factors common to both diabetes and cancer, 3) possible biologic links between diabetes and cancer risk, and 4) whether diabetes treatments influence risk of cancer or cancer prognosis. In addition, key unanswered questions for future research are posed.

[1]  H. Grosse.  [Diabetes and cancer]. , 1956, Deutsche Zeitschrift fur Verdauungs- und Stoffwechselkrankheiten.

[2]  N. Legros,et al.  Influence of insulin deprivation on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats subjected to alloxan diabetes and food restriction. , 1972, Cancer research.

[3]  M. Pras,et al.  Serum amyloid A (SAA) variations in patients with cancer: correlation with disease activity, stage, primary site, and prognosis. , 1986, Journal of clinical pathology.

[4]  L. Bjeldanes,et al.  Identification of the mutagens in cooked beef. , 1986, Environmental health perspectives.

[5]  K. Turteltaub,et al.  Role of sulfation and acetylation in the activation of 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine to intermediates which bind DNA. , 1990, Mutation research.

[6]  R. Brand,et al.  Elevated insulin receptor content in human breast cancer. , 1990, The Journal of clinical investigation.

[7]  C. la Vecchia,et al.  Medical history and primary liver cancer. , 1990, Cancer research.

[8]  N Ito,et al.  A new colon and mammary carcinogen in cooked food, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). , 1991, Carcinogenesis.

[9]  D. Powell,et al.  Insulin inhibits transcription of the human gene for insulin-like growth factor-binding protein-1. , 1991, The Journal of biological chemistry.

[10]  M. Butler,et al.  Metabolic activation of carcinogenic heterocyclic aromatic amines by human liver and colon. , 1991, Carcinogenesis.

[11]  M. Rechler,et al.  Insulin rapidly decreases insulin-like growth factor-binding protein-1 gene transcription in streptozotocin-diabetic rats. , 1992, Molecular endocrinology.

[12]  K. Turteltaub,et al.  Fate and distribution of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in mice at a human dietary equivalent dose. , 1992, Cancer research.

[13]  N Ito,et al.  Dose-dependence of 2-amino-1-methy1–6-phenylimidazo[4, 5-b]-pyridine (PhIP) carcinogenicity in rats , 1993 .

[14]  S. Thorgeirsson,et al.  Contribution of CYP1A1 and CYP1A2 to the activation of heterocyclic amines in monkeys and human. , 1994, Carcinogenesis.

[15]  A. Boobis,et al.  Metabolism of the food derived mutagen and carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine (PhIP) by human liver microsomes. , 1994, Carcinogenesis.

[16]  S. Venitt,et al.  Genotoxicity of human mammary lipid. , 1996, Cancer research.

[17]  T. Sugimura,et al.  DNA adduct formation, cell proliferation and aberrant crypt focus formation induced by PhIP in male and female rat colon with relevance to carcinogenesis. , 1996, Carcinogenesis.

[18]  S. Haffner,et al.  Waist circumference as the best predictor of noninsulin dependent diabetes mellitus (NIDDM) compared to body mass index, waist/hip ratio and other anthropometric measurements in Mexican Americans--a 7-year prospective study. , 1997, Obesity research.

[19]  C. la Vecchia,et al.  Selected medical conditions and risk of breast cancer. , 1997, British Journal of Cancer.

[20]  M. Mathieu,et al.  Insulin receptor expression and clinical outcome in node-negative breast cancer. , 1997, Proceedings of the Association of American Physicians.

[21]  David J Hunter,et al.  Circulating concentrations of insulin-like growth factor I and risk of breast cancer , 1998, The Lancet.

[22]  C. Mantzoros,et al.  Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. , 1998, Journal of the National Cancer Institute.

[23]  A. Renehan,et al.  Response: More About: Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF- Binding Protein-3 , 1999 .

[24]  S. Venitt,et al.  Heterocyclic aromatic amines induce DNA strand breaks and cell transformation. , 1999, Carcinogenesis.

[25]  F. Darroudi,et al.  Genotoxic effects of heterocyclic aromatic amines in human derived hepatoma (HepG2) cells. , 1999, Mutagenesis.

[26]  Who Consultation on Obesity.  Obesity: preventing and managing the global epidemic. Report of a WHO consultation. , 2000, World Health Organization technical report series.

[27]  L. Schäffer,et al.  Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. , 2000, Diabetes.

[28]  H. Glatt,et al.  N-Acetyltransferases, sulfotransferases and heterocyclic amine activation in the breast. , 2001, Pharmacogenetics.

[29]  G. Atsumi,et al.  Magnitude of Peroxisome Proliferator-Activated Receptor-γ Activation is Associated With Important and Seemingly Opposite Biological Responses in Breast Cancer Cells , 2001, Journal of Investigative Medicine.

[30]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[31]  J. Halperin,et al.  Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. , 2001, Cancer research.

[32]  E. Giovannucci.  Insulin, insulin-like growth factors and colon cancer: a review of the evidence. , 2001, The Journal of nutrition.

[33]  K Ohta,et al.  Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. , 2001, The Journal of clinical endocrinology and metabolism.

[34]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[35]  J. Thorburn,et al.  15-Deoxy-delta12,14-prostaglandin J2-induced apoptosis does not require PPARgamma in breast cancer cells. , 2002, Journal of lipid research.

[36]  H. Glatt,et al.  Heterologous expression of human N-acetyltransferases 1 and 2 and sulfotransferase 1A1 in Salmonella typhimurium for mutagenicity testing of heterocyclic amines. , 2002, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[37]  Kevin P. High,et al.  15-Deoxy-Δ12,14-prostaglandin J2-induced apoptosis does not require PPARγ in breast cancer cells Published, JLR Papers in Press, August 16, 2002. DOI 10.1194/jlr.M200224-JLR200 , 2002, Journal of Lipid Research.

[38]  C. Friedenreich,et al.  Physical activity and cancer prevention: etiologic evidence and biological mechanisms. , 2002, The Journal of nutrition.

[39]  A. Covaci,et al.  Distribution of organobrominated and organochlorinated contaminants in Belgian human adipose tissue. , 2002, Environmental research.

[40]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[41]  Rashmi Sinha,et al.  An epidemiologic approach to studying heterocyclic amines. , 2002, Mutation research.

[42]  Michael J Thun,et al.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. , 2003, The New England journal of medicine.

[43]  JoAnn E Manson,et al.  Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. , 2003, Diabetes care.

[44]  I-Min Lee,et al.  Physical activity and cancer prevention--data from epidemiologic studies. , 2003, Medicine and science in sports and exercise.

[45]  M. Thun,et al.  Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. , 2004, American journal of epidemiology.

[46]  B. Spiegelman,et al.  Use of the Peroxisome Proliferator-Activated Receptor (PPAR) γ Ligand Troglitazone as Treatment for Refractory Breast Cancer: A Phase II Study , 2003, Breast Cancer Research and Treatment.

[47]  E. Rimm,et al.  Diabetes mellitus and risk of prostate cancer (United States) , 2004, Cancer Causes & Control.

[48]  J. Arnsten,et al.  Effect of alcohol consumption on diabetes mellitus: a systematic review. , 2004, Annals of internal medicine.

[49]  Matthias Egger,et al.  Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis , 2004, The Lancet.

[50]  E. Calle,et al.  Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms , 2004, Nature Reviews Cancer.

[51]  D. Silverman,et al.  Cancer risk in patients with diabetes mellitus , 1991, Cancer Causes & Control.

[52]  R. Glasgow,et al.  Smoking and diabetes. , 2004, Diabetes care.

[53]  M. Thun,et al.  Diabetes mellitus and pancreaticcancer mortality in a prospectivecohort of United States adults , 1998, Cancer Causes & Control.

[54]  K. Bogen,et al.  Estimates of heterocyclic amine intake in the US population. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[55]  Claus Lindbjerg Andersen,et al.  Normalization of Real-Time Quantitative Reverse Transcription-PCR Data: A Model-Based Variance Estimation Approach to Identify Genes Suited for Normalization, Applied to Bladder and Colon Cancer Data Sets , 2004, Cancer Research.

[56]  Simak Ali,et al.  The cooked food derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine is a potent oestrogen: a mechanistic basis for its tissue-specific carcinogenicity. , 2004, Carcinogenesis.

[57]  S. Hilsenbeck,et al.  Time-dependence of hazard ratios for prognostic factors in primary breast cancer , 2004, Breast Cancer Research and Treatment.

[58]  J. Felton,et al.  The impact of glucuronidation on the bioactivation and DNA adduction of the cooked-food carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in vivo. , 2005, Carcinogenesis.

[59]  S. Hankinson,et al.  Racial Differences in Premenopausal Endogenous Hormones , 2005, Cancer Epidemiology Biomarkers & Prevention.

[60]  K. Kamiya,et al.  Tumor induction by azoxymethane (AOM) and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in F344 rat gastric mucosa featuring intestinal metaplasia caused by X-irradiation. , 2005, Journal of experimental & clinical cancer research : CR.

[61]  C. Franceschi,et al.  Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice , 2005, Experimental Gerontology.

[62]  S. Hankinson,et al.  A Prospective Study of C-Peptide, Insulin-like Growth Factor-I, Insulin-like Growth Factor Binding Protein-1, and the Risk of Colorectal Cancer in Women , 2005, Cancer Epidemiology Biomarkers & Prevention.

[63]  S. Larsson,et al.  Diabetes mellitus and risk of colorectal cancer: a meta-analysis. , 2005, Journal of the National Cancer Institute.

[64]  L. Pollack,et al.  Therapy Insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer , 2005, Nature Clinical Practice Oncology.

[65]  M. Abdul-Ghani,et al.  High frequency of pre-diabetes, undiagnosed diabetes and metabolic syndrome among overweight Arabs in Israel. , 2005, The Israel Medical Association journal : IMAJ.

[66]  C. Qiu,et al.  Steroid hormone receptor expression and proliferation in rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. , 2005, Carcinogenesis.

[67]  Graham A Colditz,et al.  Physical activity and survival after breast cancer diagnosis. , 2004, JAMA.

[68]  Sui Huang,et al.  PPARγ as a therapeutic target for tumor angiogenesis and metastasis , 2005 .

[69]  L. Wagenknecht,et al.  Smoking and incidence of diabetes among U.S. adults: findings from the Insulin Resistance Atherosclerosis Study. , 2005, Diabetes care.

[70]  Dario R Alessi,et al.  Metformin and reduced risk of cancer in diabetic patients , 2005, BMJ : British Medical Journal.

[71]  R. DePinho,et al.  The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin , 2005, Science.

[72]  M. Blüher.  Transgenic animal models for the study of adipose tissue biology. , 2005, Best practice & research. Clinical endocrinology & metabolism.

[73]  M. Woodward,et al.  Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies , 2005, British Journal of Cancer.

[74]  M. Thun,et al.  Diabetes and risk of prostate cancer in a prospective cohort of US men. , 2005, American journal of epidemiology.

[75]  Sui Huang,et al.  PPARgamma as a therapeutic target for tumor angiogenesis and metastasis. , 2005, Cancer biology & therapy.

[76]  L. Shan,et al.  Global Gene Expression Profiling of Chemically Induced Rat Mammary Gland Carcinomas and Adenomas , 2005, Toxicologic pathology.

[77]  D. Hunter,et al.  Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. , 2006, Endocrine-related cancer.

[78]  M. Schulze,et al.  Body mass index history and risk of type 2 diabetes: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. , 2006, The American journal of clinical nutrition.

[79]  Alan D. Lopez,et al.  Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data , 2006, The Lancet.

[80]  Desmond E. Williams,et al.  The Burden of Diabetes Mellitus Among US Youth: Prevalence Estimates From the SEARCH for Diabetes in Youth Study , 2006, Pediatrics.

[81]  Nahum Sonenberg,et al.  Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. , 2006, Cancer research.

[82]  Anna Marie Mulligan,et al.  Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer , 2007, Breast Cancer Research and Treatment.

[83]  A. Renehan,et al.  Obesity and cancer risk: the role of the insulin–IGF axis , 2006, Trends in Endocrinology & Metabolism.

[84]  F Berrino,et al.  IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC). , 2006, Endocrine-related cancer.

[85]  E. Giovannucci,et al.  A Meta-analysis of Diabetes Mellitus and the Risk of Prostate Cancer , 2006, Cancer Epidemiology Biomarkers & Prevention.

[86]  W. Willett,et al.  Adult weight change and risk of postmenopausal breast cancer. , 2006, JAMA.

[87]  M. Thun,et al.  American Cancer Society Guidelines on Nutrition and Physical Activity for Cancer Prevention: Reducing the Risk of Cancer With Healthy Food Choices and Physical Activity , 2002, CA: a cancer journal for clinicians.

[88]  C. Friedenreich,et al.  Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). , 2006, Journal of the National Cancer Institute.

[89]  S. Majumdar,et al.  Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin , 2006, Diabetes Care.

[90]  Sharla Montvel-Cohen.  "Search for diabetes in youth". , 2006, Hawaii medical journal.

[91]  Graham A Colditz,et al.  Physical activity and survival after colorectal cancer diagnosis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  E. Giovannucci,et al.  The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. , 2007, Gastroenterology.

[93]  L. Maile,et al.  Role of the integrin αVβ3 in mediating increased smooth muscle cell responsiveness to IGF-I in response to hyperglycemic stress , 2007 .

[94]  N. Sonenberg,et al.  Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. , 2007, Cancer research.

[95]  S. Amin,et al.  Glucuronidation of PhIP and N-OH-PhIP by UDP-glucuronosyltransferase 1A10. , 2007, Carcinogenesis.

[96]  J. Cornuz,et al.  Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. , 2007, JAMA.

[97]  Graham A Colditz,et al.  Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women. , 2006, Journal of the National Cancer Institute.

[98]  G. Bray,et al.  Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes , 2007, Diabetes Care.

[99]  E. Siegel,et al.  Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  T. Rustan,et al.  Metabolic activation of aromatic and heterocyclicN-hydroxyarylamines by wild-type and mutant recombinant human NAT1 and NAT2 acetyltransferases , 2007, Archives of Toxicology.

[101]  C. Mantzoros,et al.  Diabetes mellitus and risk of endometrial cancer: a meta-analysis , 2007, Diabetologia.

[102]  Lawrence H. Kushi,et al.  Erratum: American Cancer Society guidelines on nutrition and physical activity for cancer prevention: Reducing the risk of cancer with healthy food choices and physical activity (CA - A Cancer Journal for Clinicians (2006) 56, (254-281)) , 2007 .

[103]  B. Zinman,et al.  The impact of diabetes on survival following breast cancer , 2008, Breast Cancer Research and Treatment.

[104]  L. Maile,et al.  Role of the integrin alphaVbeta3 in mediating increased smooth muscle cell responsiveness to IGF-I in response to hyperglycemic stress. , 2007, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[105]  B. Littenberg,et al.  Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System , 2007, BMC medicine.

[106]  C. Roberts,et al.  Differential Activation of Insulin Receptor Substrates 1 and 2 by Insulin-Like Growth Factor-Activated Insulin Receptors , 2007, Molecular and Cellular Biology.

[107]  J. Manson,et al.  Circulating insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohorts , 2007, British Journal of Cancer.

[108]  D. Hum,et al.  Safety issues and prospects for future generations of PPAR modulators. , 2007, Biochimica et biophysica acta.

[109]  D. Yee,et al.  Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. , 2007, Cancer research.

[110]  N. Qizilbash,et al.  Cancer risks in thiazolidinedione users compared to other anti‐diabetic agents , 2007, Pharmacoepidemiology and drug safety.

[111]  J. Kopecký,et al.  White adipose tissue: storage and effector site for environmental pollutants. , 2007, Physiological research.

[112]  J. Manson,et al.  Circulating insulin-like growth factor binding protein-1 and the risk of pancreatic cancer. , 2007, Cancer research.

[113]  F. Hu,et al.  Glycemic index, glycemic load, and cereal fiber intake and risk of type 2 diabetes in US black women. , 2007, Archives of internal medicine.

[114]  M. Pollak,et al.  Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. , 2008, Endocrine-related cancer.

[115]  J. Shikany,et al.  Dietary carbohydrate, glycemic index, and glycemic load in relation to colorectal cancer risk in the Women’s Health Initiative , 2008, Cancer Causes & Control.

[116]  H. Arnqvist,et al.  Mitogenic Effect of the Insulin Analogue Glargine in Malignant Cells in Comparison with Insulin and IGF-I , 2008, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[117]  H. Masoudi,et al.  Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. , 2008, Cancer research.

[118]  S. Jabbour.  Primary care physicians and insulin initiation: multiple barriers, lack of knowledge or both? , 2008, International journal of clinical practice.

[119]  P. Pisani.  Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies , 2008, Archives of physiology and biochemistry.

[120]  M. Stampfer,et al.  Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. , 2008, The Lancet. Oncology.

[121]  M. Pollak,et al.  Insulin and insulin-like growth factor signalling in neoplasia , 2008, Nature Reviews Cancer.

[122]  P. Mitchell,et al.  Glycemic index, glycemic load, and chronic disease risk--a meta-analysis of observational studies. , 2008, The American journal of clinical nutrition.

[123]  D. Balzi,et al.  Sulphonylureas and cancer: a case–control study , 2008, Acta Diabetologica.

[124]  A. Wolff,et al.  Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. , 2008, JAMA.

[125]  J. Menéndez,et al.  The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells , 2009, Cell cycle.

[126]  A. Renehan.  Bariatric surgery, weight reduction, and cancer prevention. , 2009, The Lancet. Oncology.

[127]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[128]  Hua Yu,et al.  STATs in cancer inflammation and immunity: a leading role for STAT3 , 2009, Nature Reviews Cancer.

[129]  Robert H. Bell,et al.  Insulin receptor expression by human prostate cancers , 2009, The Prostate.

[130]  V. Ehemann,et al.  Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. , 2009, Endocrine-related cancer.

[131]  J. Menéndez,et al.  Genome-wide inhibitory impact of the AMPK activator metformin on [kinesins, tubulins, histones, auroras and polo-like kinases] M-phase cell cycle genes in human breast cancer cells , 2009, Cell cycle.

[132]  U. Smith,et al.  Does diabetes therapy influence the risk of cancer? , 2009, Diabetologia.

[133]  F. Visseren,et al.  Obesity and Cancer: The Role of Dysfunctional Adipose Tissue , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[134]  J. Lindström,et al.  Association of sequence variations in the gene encoding insulin-like growth factor binding protein 5 with adiponectin , 2009, International Journal of Obesity.

[135]  S. Mayne,et al.  Dietary glycemic index, glycemic load, and risk of cancer: a prospective cohort study. , 2008, American journal of epidemiology.

[136]  K. Straif,et al.  A review of human carcinogens--Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. , 2009, The Lancet. Oncology.

[137]  P. Butler.  Insulin Glargine Controversy: A Tribute to the Editorial Team at Diabetologia , 2009, Diabetes.

[138]  M. Jensen,et al.  Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. , 2009, The American journal of medicine.

[139]  P. Goodwin,et al.  Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, Wolff AC, Brancati FL. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 2008 300(23):2754-64. PMID: 19088353 , 2009 .

[140]  S. Sorrenti,et al.  The urokinase plasminogen activator system: a target for anti-cancer therapy. , 2009, Current cancer drug targets.

[141]  F. Ondrey,et al.  Peroxisome Proliferator-Activated Receptor γ Pathway Targeting in Carcinogenesis: Implications for Chemoprevention , 2009, Clinical Cancer Research.

[142]  Jürgen Rehm,et al.  Alcohol as a Risk Factor for Type 2 Diabetes , 2009, Diabetes Care.

[143]  G. Landman,et al.  Metformin Associated With Lower Cancer Mortality in Type 2 Diabetes , 2009, Diabetes Care.

[144]  A. Thor,et al.  Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro , 2009, Cell cycle.

[145]  M. Cazzaniga,et al.  Is it Time to Test Metformin in Breast Cancer Clinical Trials? , 2009, Cancer Epidemiology Biomarkers & Prevention.

[146]  Funda Meric-Bernstam,et al.  Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[147]  the Scottish Diabetes Research Network Epidemiology Group.  Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group , 2009, Diabetologia.

[148]  E. Gale,et al.  The influence of glucose-lowering therapies on cancer risk in type 2 diabetes , 2009, Diabetologia.

[149]  K. Kinzler,et al.  Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells , 2009, Science.

[150]  L. Hemkens,et al.  Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study , 2009, Diabetologia.

[151]  D. Nathan.  Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes , 2009, Diabetes Care.

[152]  J. McGill,et al.  Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study , 2009, Diabetologia.

[153]  H. Colhoun,et al.  Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group , 2009, Diabetologia.

[154]  Do cancer cells care if their host is hungry? , 2009, Cell metabolism.

[155]  J. Stanford,et al.  Metformin use and prostate cancer in Caucasian men: results from a population-based case–control study , 2009, Cancer Causes & Control.

[156]  David M. Sabatini,et al.  Tumours with PI3K activation are resistant to dietary restriction , 2009, Nature.

[157]  D. Panagiotakos,et al.  Dietary patterns and prevention of type 2 diabetes: from research to clinical practice; a systematic review. , 2009, Current diabetes reviews.

[158]  G. Steineck,et al.  Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden , 2009, Diabetologia.

[159]  H. Werner,et al.  Insulin analogues display IGF‐I‐like mitogenic and anti‐apoptotic activities in cultured cancer cells , 2009, Diabetes/metabolism research and reviews.

[160]  L. Shaw,et al.  Expression and function of the insulin receptor substrate proteins in cancer , 2009, Cell Communication and Signaling.

[161]  Kevin Struhl,et al.  Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. , 2009, Cancer research.

[162]  Ross J. Harris,et al.  Circulating insulin‐like growth factor peptides and prostate cancer risk: A systematic review and meta‐analysis , 2009, International journal of cancer.

[163]  C. Currie,et al.  The longest ever randomised controlled trial of insulin glargine: study design and HbA1c findings , 2009, Diabetologia.

[164]  J. Meyerhardt,et al.  Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[165]  Bolin Liu,et al.  Metformin induces unique biological and molecular responses in triple negative breast cancer cells , 2009, Cell cycle.

[166]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[167]  Ralph A. DeFronzo,et al.  From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus , 2009, Diabetes.

[168]  F. Ovalle.  Metformin Associated With Lower Cancer Mortality in Type 2 Diabetes: ZODIAC-16 , 2010 .

[169]  A. Nicolucci.  Epidemiological aspects of neoplasms in diabetes , 2010, Acta Diabetologica.

[170]  Jun Hee Lee,et al.  Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF Expression , 2010, Cell.

[171]  H. Gerstein.  Does insulin therapy promote, reduce, or have a neutral effect on cancers? , 2010, JAMA.

[172]  Andrew W Roddam,et al.  Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies , 2010, The Lancet. Oncology.

[173]  M. Pollak,et al.  Insulin analogues and cancer risk: cause for concern or cause célèbre? , 2010, International journal of clinical practice.

[174]  A. Morisset,et al.  Prevention of gestational diabetes mellitus: a review of studies on weight management , 2010, Diabetes/metabolism research and reviews.

[175]  R. Bergenstal,et al.  Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications. , 2010, The American journal of medicine.

[176]  Choon-Sik Park,et al.  Identification and validation of SAA as a potential lung cancer biomarker and its involvement in metastatic pathogenesis of lung cancer. , 2011, Journal of proteome research.

[177]  R. Sinha,et al.  Comparability and repeatability of methods for estimating the dietary intake of the heterocyclic amine contaminant 2-amino-1-methyl-6-phenylimidazo[4,5b]pyridine (PhIP) , 2012, Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment.

[178]  Guang-xun Li,et al.  Dietary Carcinogen 2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]Pyridine–Induced Prostate Carcinogenesis in CYP1A-Humanized Mice , 2012, Cancer Prevention Research.

[179]  An Pan,et al.  Red meat consumption and mortality: results from 2 prospective cohort studies. , 2012, Archives of internal medicine.